Ocugen to Unveil Phase 2 Data for Geographic Atrophy Therapy
Event summary
- Ocugen will host a webcast on March 24, 2026, at 8 a.m. EDT to discuss Phase 2 clinical trial data for OCU410, a modifier gene therapy for geographic atrophy (GA).
- Key opinion leaders (KOLs) including Lejla Vajzovic, MD, Jay Chhablani, MD, Victor H. Gonzalez, MD, and Syed M. Shah, MD will participate in the webcast.
- The data being discussed is from the Phase 2 ArMaDa clinical trial evaluating OCU410 for late-stage dry age-related macular degeneration (dAMD).
- The webcast will be available on the events section of the Ocugen investor site, with a replay available afterward.
The big picture
Ocugen's upcoming webcast highlights the critical phase of clinical development for OCU410, a therapy targeting a significant unmet need in late-stage dry age-related macular degeneration. The involvement of key opinion leaders underscores the strategic importance of this data release in shaping the therapeutic landscape for geographic atrophy. The outcome could influence investor confidence and competitive dynamics in the gene therapy space.
What we're watching
- Clinical Efficacy
- How the Phase 2 data for OCU410 will impact the perceived efficacy and potential market adoption of the therapy for geographic atrophy.
- Regulatory Pathway
- Whether the data will accelerate or decelerate the regulatory approval process for OCU410.
- Competitive Positioning
- The pace at which Ocugen can differentiate OCU410 from competing therapies in the geographic atrophy treatment landscape.
Related topics